期刊
NATURE MEDICINE
卷 24, 期 10, 页码 1550-+出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41591-018-0136-1
关键词
-
资金
- Cancer Immunologic Data Commons grant of the National Cancer Institute (NCI) [1U24CA224316-01]
- Pathway to Independence Award grant of NCI [1K99CA218900-01]
- Specialized Center grant of NCI [1P50CA206963-01]
- Breast Cancer Research Foundation
Cancer treatment by immune checkpoint blockade (ICB) can bring long-lasting clinical benefits, but only a fraction of patients respond to treatment. To predict ICB response, we developed TIDE, a computational method to model two primary mechanisms of tumor immune evasion: the induction of T cell dysfunction in tumors with high infiltration of cytotoxic T lymphocytes (CTL) and the prevention of T cell infiltration in tumors with low CTL level. We identified signatures of T cell dysfunction from large tumor cohorts by testing how the expression of each gene in tumors interacts with the CTL infiltration level to influence patient survival. We also modeled factors that exclude T cell infiltration into tumors using expression signatures from immunosuppressive cells. Using this framework and pre-treatment RNA-Seq or NanoString tumor expression profiles, TIDE predicted the outcome of melanoma patients treated with first-line anti-PD1 or anti-CTLA4 more accurately than other biomarkers such as PD-L1 level and mutation load. TIDE also revealed new candidate ICB resistance regulators, such as SERPINB9, demonstrating utility for immunotherapy research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据